Abstract
Vitamin D is a steroid hormone which binds to the vitamin D receptor (VDR) and has been implicated in carcinogenesis. Pre-clinical data on the VDR demonstrates a direct correlation between the vitamin and cell growth, differentiation, and apoptosis. Through nuclear transcription as well as cytoplasmic pathway induction, binding of the active form of vitamin D, calcitriol, to the VDR has been shown to mechanistically affect multiple carcinogenic cell lines. Mouse models have been further utilized to demonstrate the in vivo effects of calcitriol and the VDR on tumorogenesis. While pre-clinical data supporting the potential of calcitriol as a cancer therapeutic agent abounds, evidence from clinical trials remains sparse. Most studies thus far do not clearly demonstrate a correlation between intermittent doses of calcitriol and decreased rates of development or recurrence of malignancy. However, few large clinical trials have been performed, and some of the smaller studies that have been done demonstrate decreases in cancer markers, fewer rates of progression, and rarely complete remissions. The inconsistent results suggest that our understanding of the potential anti-tumor effects of vitamin D is limited, and further clinical investigation is necessary.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Beer TM, Myrthue A, Eilers KM. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World J Urol. 2005;23:28–32.
Beer TM, Javle MM, et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007a;59(5):581–7.
Beer TM, Ryan CW, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol. 2007b;25(6):669–74.
Carlberg C, Dunlop TW. The impact of chromatin organization of vitamin D target genes. Anticancer Res. 2006;26(4A):2637–45.
Chaudhry M, Sundaram S, et al. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol. 2001;47(5):429–36.
Dalhoff K, Dancey J, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer. 2003;89(2):252–7.
Deeb KK, Trump DL, et al. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700.
Eitenmiller RR, Ye L, Landen Jr WO. Vitamin analysis for the health and food sciences. 2nd ed. Florida: CRC Press; 2008. p. 83–112.
Freedman DM, Chang SC, Falk RT, et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2008;17:889–94.
Giovannucci E. The epidemiology of vitamin D. In: Trump DL, Johnson CS, editors. Vitamin D and cancer. New York: Springer; 2011. p. 73–97.
Goodwin PJ, Ennis M, et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27(23):3757–63.
Gross C, Stamey T, et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998;159(6):2035–9. discussion 2039–2040.
Holick MF. Vitamin D status: measurement, interpretation and clinical application. Ann Epidemiol. 2009;19(2):73–8.
Larriba MJ, Munoz A. Mechanisms of resistance to vitamin D action in human cancer cells. In: Holick MF, editor. Vitamin D: physiology, molecular biology, and clinical applications. New York: Humana Press; 2010. p. 325–33.
Ma Y, Yu WD, et al. 1alpha,25-dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther. 2008;7(9):3047–55.
Ng K, Meyerhardt JA, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26:2984–91.
Osborn JL, Schwartz GG, et al. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol. 1995;1(5):195–8.
Reichrath J. Using vitamin D for management of human diseases. In: Hermann W, Obeid R, editors. Vitamins in the prevention of human disease. Homburg: De Gruyter; 2011. p. 399–407.
Robsahm TE, Tretli S, Dahlback A, et al. Vitamin D3 from sunlight may improve the prognosis of breast, colon, and prostate cancer. Cancer Causes Control. 2004;15:149–58.
Rustin GJ, Quinnell TG, et al. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer. 1996;74(9):1479–81.
Scher HI, Jia X, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. Clin Oncol. 2011;29(16):2191–8.
Swami S, Krishnan AV, et al. Dietary vitamin d3 and 1,25-dihydroxyvitamin d3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology. 2012;153(6):2576–87.
Thorne J, Campbell MJ. The molecular cancer biology of the VDR. In: Trump DL, Johnson CS, editors. Vitamin D and cancer. New York: Springer; 2011. p. 25–52.
Trump DL, Deeb KK, et al. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010;16(1):1–9.
Webb GP. Dietary supplements and functional foods. 2nd ed. Oxford: Blackwell Publishing; 2011. p. 89–95.
Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004;80(suppl):1721S–4.
Zhou W, Heist RS, Liu G, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2007;25(5):479–85.
Zittermann A. Vitamin D: cholecalciferol. In: Hermann W, Obeid R, editors. Vitamins in the prevention of human disease. Homburg: De Gruyter; 2011. p. 363–95.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this entry
Cite this entry
Crew, K.D. (2017). VDR. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_54
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0717-2_54
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0716-5
Online ISBN: 978-1-4419-0717-2
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences